HS 1421

Drug Profile

HS 1421

Alternative Names: HS1421

Latest Information Update: 26 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyowa Hakko
  • Class Heart failure therapies
  • Mechanism of Action Atrial peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetic nephropathies; Heart failure

Most Recent Events

  • 26 Sep 2006 Discontinued - Preclinical for Diabetic nephropathies in Japan (unspecified route)
  • 26 Sep 2006 Discontinued - Preclinical for Heart failure in USA (unspecified route)
  • 24 Aug 1999 A preclinical study has been added to the Heart Failure pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top